Zosano Pharma Corporation (ZSAN)
Stock Price:
$1.64 USD
0.28 (20.59%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $1.65 +0.01 (0.61%) Aug 14, 7:59 PM
Key Info
| Market Cap |
112.48M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-35.39M |
| Shares Out |
54.36M |
| EPS (ttm) |
-1.11 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$1.64 |
| Previous Close |
$1.36 |
| Change ($) |
0.28 |
| Change (%) |
20.59% |
| Day's Open |
1.36 |
| Day's Range |
1.35 - 1.75 |
| Day's Volume |
13,827,436 |
| 52-Week Range |
0.41 - 3.21 |
More Stats
| Market Cap |
112.48M |
| Enterprise Value |
119.21M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
54.36M |
| Float |
68.46M |
| EPS (basic) |
-1.38 |
| EPS (diluted) |
-1.11 |
| FCF / Share |
-0.78 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.68M |
| Short Ratio |
1.98 |
| Short % of Float |
11.01% |
| Beta |
2.71 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.54 |
| Revenue |
n/a |
| Operating Income |
-34.60M |
| Net Income |
-35.39M |
| Free Cash Flow |
-42.90M |
| Net Cash |
-6.73M |
| Net Cash / Share |
-0.10 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-46.25% |
| ROE |
-188.88% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.33*
(164.02% upside)
Low
2.00
Current: $1.64
High
7.00
Target: 4.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | 0.31 | 2.86 | 4.25 |
| Revenue Growth | - | - | - | - | -89.06% | -32.68% | - |
| Gross Profit | - | - | - | - | 0.31 | 2.76 | 4.25 |
| Operating Income | -37.20 | -35.38 | -28.37 | -28.63 | -26.37 | -12.61 | -7.97 |
| Net Income | -37.59 | -35.36 | -29.11 | -29.83 | -28.43 | -14.24 | -5.61 |
| Shares Outstanding | 16.38 | 9.45 | 1.73 | 0.69 | 0.57 | 0.26 | 0.26 |
| Earnings Per Share | -2.29 | -3.74 | -16.82 | -43.36 | -49.80 | -55.60 | -22.00 |
| Operating Cash Flow | -34.82 | -29.12 | -26.84 | -25.69 | -24.16 | -10.92 | -3.72 |
| Capital Expenditures | -11.76 | -5.48 | -1.22 | -0.22 | -0.43 | -1.18 | -0.90 |
| Free Cash Flow | -46.58 | -34.60 | -28.06 | -25.91 | -24.59 | -12.09 | -4.62 |
| Cash & Equivalents | 6.77 | 23.46 | 12.11 | 15.04 | 36.97 | 1.25 | 5.98 |
| Total Debt | 17.72 | 6.83 | 6.69 | 12.54 | 15.27 | 22.06 | 13.32 |
| Net Cash / Debt | -10.95 | 16.63 | 5.42 | 2.50 | 21.70 | -20.81 | -7.34 |
| Assets | 37.67 | 35.78 | 18.00 | 20.91 | 45.34 | 13.34 | 22.08 |
| Liabilities | 28.28 | 17.07 | 10.95 | 16.42 | 18.84 | 26.74 | 21.61 |
| Book Value | 9.39 | 18.71 | 7.05 | 4.49 | 26.50 | -13.40 | 0.48 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Zosano Pharma Corporation |
| Country |
United States |
| Employees |
56 |
| CEO |
Steven Lo |
Stock Information
| Ticker Symbol |
ZSAN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ZSAN |
| IPO Date |
January 27, 2015 |
Description
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.